What Is OMass Therapeutics

OMass is an Oxford University spin-out backed by Syncona Ltd and Oxford Sciences Innovation that is harnessing high-resolution native mass spectrometry and other biophysical technologies to drive drug discovery in high definition for immunology and genetic disease.

The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulation of complex formation, with both effects, binding and function, being measured by a change in mass. These methods are being applied to drug discovery for a variety of complex targets, focusing on membrane receptors.

The

Science

We are developing novel medicines using our suite of proprietary technologies based on high-resolution mass spectrometry of intact protein assemblies.

Read More

Overview

About Us

We are a biotechnology company using structural mass spectrometry to discover novel medicines.

Read More

Latest News

OMass Therapeutics appoints Dr Nathalie Franchimont as Non-Executive Director
July 28, 2020

Oxford, 28 July 2020 – OMass Therapeutics (“OMass”), a biopharmaceutical company harnessing native mass spectrometry and other high definition biophysical technologies…

Read More
OMass Announces Publication in Nature Methods
May 15, 2020

Oxford, 15 May 2020 – OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high…

Read More
OMass Announces Acquisition of Pharmacology Capabilities from Excellerate Biosciences
February 25, 2020

– OMass acquires a pharmacology team led by industry expert, Professor Steven Charlton – Oxford, 25 February 2020 – OMass Therapeutics…

Read More
OMass Therapeutics Announces £27.5 Million Extended Series A Financing
February 17, 2020

– Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders – Oxford, 17 February 2020 –…

Read More